17:12:46 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



News for U:MNOV from 2023-03-29 to 2024-03-28 - 18 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-26 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
2024-03-20 19:00U:MNOVNews ReleaseMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
2024-03-12 06:30U:MNOVNews ReleaseMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
2024-01-17 06:00U:MNOVNews ReleaseMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
2023-12-21 18:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
2023-12-06 18:00U:MNOVNews ReleaseMediciNova Receives a Notice of Decision to Grant for ‚  a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
2023-11-19 18:00U:MNOVNews ReleaseMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
2023-10-27 01:00U:MNOVNews ReleaseMediciNova ¢ € ™s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
2023-10-10 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Allowance for ‚  a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
2023-10-04 19:00U:MNOVNews ReleaseMediciNova Receives Gene Therapy Milestone Payment
2023-09-27 19:00U:MNOVNews ReleaseMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
2023-08-17 19:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
2023-08-16 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Intention to Grant for ‚  a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
2023-08-15 19:00U:MNOVNews ReleaseMediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
2023-08-14 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
2023-06-29 06:00U:MNOVNews ReleaseMediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
2023-05-14 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Intention to Grant for ‚  a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
2023-04-30 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada